Liver function tests and metabolic-associated fatty liver disease: Changes in upper normal limits, does it really matter?

Figure 1 Fibrosis stage in three subgroups of patients stratified for alanine aminotransferase levels. ALT: Alanine aminotransferase; pts: Patients.

Figure 2 Diagnosis of metabolic-associated steato-hepatitis in three subgroups of patients stratified for alanine aminotransferase levels. ALT: Alanine aminotransferase; pts: Patients; MASH: Metabolic-associated steato-hepatitis.

Figure 3 Receiver operating characteristic areas under the curves for liver function tests and non-invasive markers of fibrosis for diagnosis advanced fibrosis (F ≥ F3) and definite metabolic-associated steato-hepatitis (Non-alcoholic fatty liver disease activity score ≥ 5). A: Liver function tests and non-invasive markers of fibrosis for diagnosis advanced fibrosis (F ≥ F3); B: Liver function tests and non-invasive markers of fibrosis for diagnosis definite metabolic-associated steato-hepatitis (Non-alcoholic fatty liver disease activity score ≥ 5). ROC: Receiver operating characteristic; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; NAFLD: Non-alcoholic fatty liver disease; FIB: Fibrosis.